-

Nexus Pharmaceuticals Launches Tranexamic Acid

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announced the launch of Tranexamic Acid. This milestone is another step for Nexus in its mission to provide life-saving medication to those who need it most.

“We are very excited to be adding Tranexamic Acid to our product portfolio,” says Vince LoPiccolo, Vice President of Sales at Nexus. “Antifibrinolytic Agents, such as Tranexamic Acid, are crucial to have available in operating rooms and we are proud to contribute to the supply.”

Tranexamic Acid is now available in cartons of 10 bags. Order through your Wholesaler today.

To learn more about Nexus Pharmaceuticals’ products, visit www.nexuspharma.net/molecules

About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals, LLC., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most.

Contacts

Grace Conroy
gconroy@nexuspharma.net
847-527-7490

Industry:

Nexus Pharmaceuticals, LLC

Release Versions
English

Contacts

Grace Conroy
gconroy@nexuspharma.net
847-527-7490

More News From Nexus Pharmaceuticals, LLC

Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the U.S Food and Drug Administration (FDA) approval of Tacrolimus Injection 5 mg/mL. Nexus’ Tacrolimus Injection is the first and only vial that will be available. “We are pleased to share the FDA approval of Tacrolimus Injection. Tacrolimus is a critical treatment option for patients requiring immunosuppressive therapy, enhancing their quality of life, and reducing the risk of organ rejection,” says Usman Ahmed, Chief Ex...

Nexus Pharmaceuticals Receives FDA Approval for Methylene Blue Injection, USP

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the U.S. Food and Drug Administration (FDA) approval of Methylene Blue Injection, USP. Methylene Blue is an oxidation-reduction agent that offers treatment of acquired methemoglobinemia. “We are pleased to strengthen the supply of an AP-rated and TIAA compliant Methylene Blue Injection,” says Sridhar Desikan, Chief Scientific Officer at Nexus Pharmaceuticals. “The addition of Methylene Blue to our portfolio further emphas...

Nexus Pharmaceuticals Launches Baclofen Injection, USP

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Today, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP. This sterile solution is designed for intrathecal administration and serves as a muscle relaxant and antispastic. Baclofen Injection is often used to treat patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms. “By adding Baclofen to our portfolio, we continue to lead the charge in minimizing healthcare challenges...
Back to Newsroom